Minocycline as a substitute for doxycycline in targeted scenarios: A systematic review

Open Forum Infectious Diseases

Volumn 2, Issue 4, 2015, Pages

  Carris, Nicholas W ^a,b   Pardo, Joe ^c   Montero, Jose ^b   Shaeer, Kristy M ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alternatives; Doxycycline; Minocycline; Shortage; Substitution

Indexed keywords

DOXYCYCLINE; MINOCYCLINE; QUINOLONE;

ALTERNATIVE MEDICINE; ANTIBODY RESPONSE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; ERYTHEMA CHRONICUM MIGRANS; HEALTH CARE DELIVERY; HUMAN; LIPOPHILICITY; LYME DISEASE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RICKETTSIA JAPONICA; RICKETTSIOSIS; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW;

EID: 85014246887     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv178     Document Type: Review

References (82)

1. Centers for Disease Control and Prevention. Nationwide Shortage of Doxycycline: Resources for Providers and Recommendations for Patient Care. Available at: http://emergency.cdc.gov/han/han00349.asp. Accessed 7 August 2015.
2. Quadri F, Mazer-Amirshahi M, Fox ER, et al. Antibacterial drug shortages from 2001 to 2013: implications for clinical practice. Clin Infect Dis 2015; 60:1737-42.
3. American Society of Health-System Pharmacists. ASHP Drug Shortages Resource Center. Available at: http://www.ashp.org/menu/Drug Shortages. Accessed 20 August 2015.
4. United States Senate Committee on Health, Education, Labor and Pensions. Subcommittee on Primary Health and Aging. Why are some generic drugs skyrocketing in price? 2015. Available at: http://www.help. senate.gov/hearings/why-are-some-generic-drugs-skyrocketing-inpriced. Accessed 20 August 2015.
5. Gundlapalli AV, Beekmann SE, Graham DR, Polgreen PM. Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists. Diagn Microbiol Infect Dis 2013; 75:256-9.
6. AARP Public Policy Institute. Trends in Retail Prices of Generic Prescription Drugs Widely Used by Older Americans, 2006 to 2013. Available at: http://www.aarp.org/content/dam/aarp/ppi/2015/trendsin-retail-prices-of-generic-prescription-drugs.pdf. Accessed 9 December 2015.
7. Minocin® [package insert]. Monza, Italy: Triax Pharmaceuticals; 2010.
8. Eisen DP. Tetracycline. In: Grayson LM, Kucers A, Crowe S, et al, eds. Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. Boca Raton, FL: CRC Press, 2010:843-50.
9. Vibramycin® [package insert]. New York, NY: Pfizer Laboratories, 2015.
10. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15:355-66.
11. Alestig K. Studies on doxycycline during intravenous and oral treatment with reference to renal function. Scand J Infect Dis 1973; 5:193-8.
12. Alestig K. Studies on the intestinal excretion of doxycycline. Scand J Infect Dis 1974; 6:265-71.
13. MahonWA, Johnson GE, Endrenyl L, et al. The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function. Scand J Infect Dis Suppl 1976; 9:24-31.
14. Steigbigel NH, Reed CW, Finland M. Absorption and excretion of five tetracycline analogues in normal young men. Am J Med Sci 1968; 255:296-312.
15. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27:1329-42.
16. Falagas ME, Vardakas KZ, Kapaskelis A, et al. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents 2015; 45:455-60.
17. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-92.
18. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27-72.
19. Cappel R, Klastersky J. Bacteriologic and clinical evaluation of minocycline, a new tetracycline. Curr Ther Res Clin Exp 1971; 13:227-33.
20. Phair JP, Hartman RE, Carleton J. Evaluation of the efficacy of minocycline therapy for staphylococcal soft-tissue infection. Antimicrob Agents and Chemother 1974; 6:551-3.
21. RaffMJ, Rogers J, Barnwell PA, Waterman N. Minocycline in staphylococcal soft-tissue infections. Arch Dermatol 1975; 111:874-6.
22. Clumeck N, Marcelis L, Amiri-Lamraski MH, Gordts B. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 1984; 13:17-22.
23. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40:1429-34.
24. Barnes EV II, Dooley DP, Hepburn MJ, Baum SE. Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin. Mil Med 2006; 171:504-7.
25. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3298-303.
26. Rogers JH, Barnwell PA, Waterman NG, et al. Clinical evaluation of intravenous minocycline. Int J Clin Pharmacol Biopharm 1977; 15:194-8.
27. Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012; 17:354-62.
28. Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012; 55:1642-9.
29. Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother 2013; 57:2252-8.
30. Miyashita N, Akaike H, Teranishi H, et al. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother 2013; 57:5181-5.
31. Weber K, Neubert U, Thurmayr R. Antibiotic therapy in early erythema migrans disease and related disorders. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 263:377-88.
32. Muellegger RR, Zoechling N, Soyer HP, et al. No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment. Arch Dermatol 1995; 131:678-82.
33. Breier F, Kunz G, Klade H, et al. Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis. Infection 1996; 24:69-72.
34. Schmidt B, Muellegger RR, Stockenhuber C, et al. Detection of Borrelia burgdorferi-specific DNA in urine specimens from patients with erythema migrans before and after antibiotic therapy. J Clin Microbiol 1996; 34:1359-63.
35. Stanek G, Breier F, Menzinger G, et al. Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three Borrelia species. Wien Klin Wochenschr 1999; 111:951-6.
36. Glatz M, Golestani M, Kerl H, Mullegger RR. Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients. Arch Dermatol 2006; 142:862-8.
37. Kodama K, Senba T, Yamauchi H, et al. Clinical study of Japanese spotted fever and its aggravating factors. J Infect Chemother 2003; 9:83-7.
38. Tenjin Y, Wada M, Oomura N, Higuchi S. [First case report of fatal Japanese spotted fever in Kumamoto Prefecture and the investigation of severe cases in Kamiamakusa City]. Kansenshogaku Zasshi 2014; 88:700-3.
39. Miyashita N, Kawai Y, Akaike H, et al. Atelectasis caused by macrolideresistant Mycoplasma pneumoniae pneumonia in an adult patient. J Infect Chemother 2013; 19:1161-6.
40. Nakata R, Motomura M, Tokuda M, et al. A case of Japanese spotted fever complicated with central nervous system involvement and multiple organ failure. Intern Med 2012; 51:783-6.
41. Inamo Y, Ishizuka Y, Hashimoto K, et al. A 7-year-old girl with subcutaneous emphysema, pneumomediastinum, pneumothorax, and pneumoretroperitoneum caused by Mycoplasma pneumoniae pneumonia. J Infect Chemother 2012; 18:247-50.
42. Kondo M, Kurokawa I, Yamanaka K, et al. Japanese spotted fever with acute hepatic failure: was it associated with Epstein-Barr virus? Int J Dermatol 2010; 49:1403-5.
43. Kondo M, Kurokawa I, Yamanaka K, et al. Topical treatment with incision and antiseptic may prevent the severity of Japan spotted fever. J Dermatol 2010; 37:835-6.
44. Takahashi T, Morozumi M, Okada T, et al. Prolonged Mycoplasma pneumoniae infection in an elderly patient with community-acquired pneumonia. J Infect Chemother 2009; 15:243-7.
45. Wada K, Sakaeda H, Aono R, Chiya S. Fulminant Japanese spotted fever-the second fatal case in Japan. Kansenshogaku Zasshi 2008; 82:77-81.
46. Tsai YS, Wu YH, Kao PT, Lin YC. African tick bite fever. J Formos Med Assoc 2008; 107:73-6.
47. Nakayama E, Hasegawa K, Morozumi M, et al. Rapid optimization of antimicrobial chemotherapy given to pediatric patients with communityacquired pneumonia using PCR techniques with serology and standard culture. J Infect Chemother 2007; 13:305-13.
48. Seki M, Ikari N, Yamamoto S, et al. Severe Japanese spotted fever successfully treated with fluoroquinolone. Intern Med 2006; 45:1323-6.
49. Noji Y, Takada N, Ishiguro F, et al. The first reported case of spotted fever in Fukui Prefecture, the northern part of central Japan. Jpn J Infect Dis 2005; 58:112-4.
50. Yanagi S, Ashitani J, Arimura Y, et al. A case of severe Chlamydia pneumoniae pneumonia requiring mechanical ventilation and complicated with disseminated intravascular coagulation. Nihon Kokyuki Gakkai Zasshi 2003; 41:840-5.
51. Kodama K, Senba T, Yamauchi H, et al. Japanese spotted fever associated with multiorgan failure. J Infect Chemother 2001; 7:247-50.
52. Iwasaki H, Mahara F, Takada N, et al. Fulminant Japanese spotted fever associated with hypercytokinemia. J Clin Microbiol 2001; 39:2341-3.
53. Tsai KH, Lu HY, Huang JH, et al. African tick bite fever in a Taiwanese traveler returning from South Africa: molecular and serologic studies. Am J Trop Med Hyg 2009; 81:735-9.
54. Johnson SE, Klein GC, Schmid GP, Feeley JC. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J Biol Med 1984; 57:549-53.
55. Miyamura S, Ohta T, Tamura A. Comparison of in vitro susceptibilities of Rickettsia prowazekii, R. rickettsii, R. sibirica and R. tsutsugamushi to antimicrobial agents. Nihon Saikingaku Zasshi 1989; 44:717-21.
56. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis 2009; 199:1379-88.
57. Li M, Masuzawa T, Wang J, et al. In-vitro and in-vivo antibiotic susceptibilities of Lyme disease Borrelia isolated in China. J Infect Chemother 2000; 6:65-7.
58. Fujita H, Yamada K, Kurita T, et al. In vitro and in vivo antibiotic susceptibility of Lyme disease Borrelia isolated from the ixodid tick in Japan. J Dermatol 1995; 22:935-8.
59. Cunha BA. Minocycline, often forgotten but preferred to trimethoprimsulfamethoxazole or doxycycline for the treatment of communityacquired meticillin-resistant Staphylococcus aureus skin and soft-tissue infections. Int J Antimicrob Agents 2013; 42:497-9.
60. Cunha BA. Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs). Eur J Clin Microbiol Infect Dis 2014; 33:1869-71.
61. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51:423-8.
62. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147-59.
63. Schwartz BS, Graber CJ, Diep BA, et al. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis 2009; 48:1483-4.
64. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25-76.
65. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371:1619-28.
66. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med 2014; 370:543-51.
67. Zheng X, Lee S, Selvarangan R, et al. Macrolide-resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis 2015; 21:1470-2.
68. RayWA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-90.
69. Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014; 12:121-7.
70. Amoxil® [package insert]. Research Triangle Park, NC: GlaxoSmith Kline; 2006.
71. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992; 327:1769-73.
72. Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. N Engl J Med 1992; 327:534-41.
73. Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. Am J Dis Child 1993; 147:945-7.
74. Costello CM, Steere AC, Pinkerton RE, Feder HM Jr. A prospective study of tick bites in an endemic area for Lyme disease. J Infect Dis 1989; 159:136-9.
75. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with singledose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345:79-84.
76. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-134.
77. Hoffmann TC, Montori VM, Del Mar C. The connection between evidence-based medicine and shared decision making. JAMA 2014; 312:1295-6.
78. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis-United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1-27.
79. Raoult D, Roussellier P, Vestris G, Tamalet J. In vitro antibiotic susceptibility of Rickettsia rickettsii and Rickettsia conorii: plaque assay and microplaque colorimetric assay. J Infect Dis 1987; 155:1059-62.
80. Raoult D, Drancourt M. Antimicrobial therapy of rickettsial diseases. Antimicrob Agents Chemother 1991; 35:2457-62.
81. Holman RC, Paddock CD, Curns AT, et al. Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001; 184:1437-44.
82. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995; 52:405-13.